How it works:
Imatinib is a tyrosine kinase inhibitor that blocks enzymes promoting the growth of cancer cells. It effectively suppresses BCR-ABL and other kinases involved in CML and tumour development.
Recommended For:
Patients with Philadelphia chromosome-positive chronic myeloid leukaemia
Individuals with unresectable or metastatic GIST
Patients with Ph+ acute lymphoblastic leukaemia
Under strict medical supervision by a haematologist or oncologist
Chronic myeloid leukaemia (Ph+ CML)
Gastrointestinal stromal tumours (GIST)
Acute lymphoblastic leukaemia (Ph+ ALL)
Myelodysplastic/myeloproliferative diseases
VEENAT tablets are taken orally, preferably with food and a full glass of water. The dosage and treatment duration are determined individually by the treating physician.
Contraindications:
Known hypersensitivity to Imatinib
Severe hepatic or renal impairment
Pregnancy and lactation
Paediatric use without specific indications
Side Effects:
Gastrointestinal symptoms (nausea, diarrhoea)
Skin rash and itching
Swelling (especially around the eyes)
Bone marrow suppression (anaemia, neutropenia, thrombocytopenia)
Liver enzyme abnormalities
